IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up
Chronic antibody-mediated rejection (AMR) is the major cause of late renal allograft loss. There is, however, no established treatment for this condition. We report the results of a prospective pilot study on an antihumoral therapy (AHT) consisting of high-dose intravenous immunoglobulin G (IVIG) an...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 August 2012
|
| In: |
Transplant international
Year: 2012, Jahrgang: 25, Heft: 11, Pages: 1165-1173 |
| ISSN: | 1432-2277 |
| DOI: | 10.1111/j.1432-2277.2012.01544.x |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1111/j.1432-2277.2012.01544.x Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1432-2277.2012.01544.x 
|
| Verfasserangaben: | Heiko Billing, Susanne Rieger, Caner Süsal, Rüdiger Waldherr, Gerhard Opelz, Elke Wühl and Burkhard Tönshoff |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1578199182 | ||
| 003 | DE-627 | ||
| 005 | 20220814204721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180802s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1432-2277.2012.01544.x |2 doi | |
| 035 | |a (DE-627)1578199182 | ||
| 035 | |a (DE-576)508199182 | ||
| 035 | |a (DE-599)BSZ508199182 | ||
| 035 | |a (OCoLC)1341015008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Billing, Heiko |d 1971- |e VerfasserIn |0 (DE-588)122639782 |0 (DE-627)70598138X |0 (DE-576)293360057 |4 aut | |
| 245 | 1 | 0 | |a IVIG and rituximab for treatment of chronic antibody-mediated rejection |b a prospective study in paediatric renal transplantation with a 2-year follow-up |c Heiko Billing, Susanne Rieger, Caner Süsal, Rüdiger Waldherr, Gerhard Opelz, Elke Wühl and Burkhard Tönshoff |
| 264 | 1 | |c 17 August 2012 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 17 August 2012 | ||
| 500 | |a Gesehen am 02.08.2018 | ||
| 520 | |a Chronic antibody-mediated rejection (AMR) is the major cause of late renal allograft loss. There is, however, no established treatment for this condition. We report the results of a prospective pilot study on an antihumoral therapy (AHT) consisting of high-dose intravenous immunoglobulin G (IVIG) and rituximab in 20 paediatric renal transplant recipients. Donor-specific HLA antibodies (HLA DSA) were quantified by Luminex-based bead array technology. Loss of eGFR decreased significantly from 7.6 ml/min/1.73 m² during 6 months prior to AHT to 2.1 ml/min/1.73 m² (P = 0.0013) during 6 months after AHT. Fourteen patients (70%) responded: nine of nine patients (100%) without and five of 11 (45%) with transplant glomerulopathy (P = 0.014). C4d positivity in PTC decreased from 40 ± 18.5% in the index biopsy to 11.6 ± 12.2% (P = 0.002) in the follow-up biopsy. In four of nine biopsies (44%) C4d staining turned negative. During 2 years of follow-up, the median loss of eGFR in each of the four 6-month periods remained significantly lower compared with prior to AHT. Class I DSA declined in response to AHT by 61% (p = 0.044), class II DSA by 63% (p = 0.033) 12 months after intervention. AHT with IVIG and rituximab significantly reduces or stabilizes the progressive loss of transplant function in paediatric patients with chronic AMR over an observation period of 2 years, apparently by lowering circulating DSA and reducing intrarenal complement activation. | ||
| 650 | 4 | |a chronic antibody-mediated rejection | |
| 650 | 4 | |a donor-specific HLA antibodies | |
| 650 | 4 | |a IVIG | |
| 650 | 4 | |a paediatric renal transplantation | |
| 650 | 4 | |a rituximab | |
| 700 | 1 | |a Rieger, Susanne |e VerfasserIn |0 (DE-588)1069693707 |0 (DE-627)1041307039 |0 (DE-576)429413440 |4 aut | |
| 700 | 1 | |a Süsal, Caner |e VerfasserIn |0 (DE-588)102648037X |0 (DE-627)726772763 |0 (DE-576)37182673X |4 aut | |
| 700 | 1 | |a Waldherr, Rüdiger |e VerfasserIn |0 (DE-588)1066699135 |0 (DE-627)817805265 |0 (DE-576)426098072 |4 aut | |
| 700 | 1 | |a Opelz, Gerhard |d 1944- |e VerfasserIn |0 (DE-588)1026480345 |0 (DE-627)726772453 |0 (DE-576)371826527 |4 aut | |
| 700 | 1 | |a Wühl, Elke |e VerfasserIn |0 (DE-588)1069939617 |0 (DE-627)823052052 |0 (DE-576)429626134 |4 aut | |
| 700 | 1 | |a Tönshoff, Burkhard |e VerfasserIn |0 (DE-588)1032445823 |0 (DE-627)738463493 |0 (DE-576)173494196 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant international |d Lausanne : Frontiers Media, 1988 |g 25(2012), 11, Seite 1165-1173 |h Online-Ressource |w (DE-627)254909744 |w (DE-600)1463183-0 |w (DE-576)074754173 |x 1432-2277 |7 nnas |a IVIG and rituximab for treatment of chronic antibody-mediated rejection a prospective study in paediatric renal transplantation with a 2-year follow-up |
| 773 | 1 | 8 | |g volume:25 |g year:2012 |g number:11 |g pages:1165-1173 |g extent:9 |a IVIG and rituximab for treatment of chronic antibody-mediated rejection a prospective study in paediatric renal transplantation with a 2-year follow-up |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1432-2277.2012.01544.x |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1432-2277.2012.01544.x |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180802 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1032445823 |a Tönshoff, Burkhard |m 1032445823:Tönshoff, Burkhard |d 910000 |d 910500 |e 910000PT1032445823 |e 910500PT1032445823 |k 0/910000/ |k 1/910000/910500/ |p 7 |y j | ||
| 998 | |g 1069939617 |a Wühl, Elke |m 1069939617:Wühl, Elke |d 910000 |d 910500 |e 910000PW1069939617 |e 910500PW1069939617 |k 0/910000/ |k 1/910000/910500/ |p 6 | ||
| 998 | |g 1026480345 |a Opelz, Gerhard |m 1026480345:Opelz, Gerhard |d 910000 |d 911600 |e 910000PO1026480345 |e 911600PO1026480345 |k 0/910000/ |k 1/910000/911600/ |p 5 | ||
| 998 | |g 1066699135 |a Waldherr, Rüdiger |m 1066699135:Waldherr, Rüdiger |d 50000 |e 50000PW1066699135 |k 0/50000/ |p 4 | ||
| 998 | |g 102648037X |a Süsal, Caner |m 102648037X:Süsal, Caner |d 910000 |d 911600 |e 910000PS102648037X |e 911600PS102648037X |k 0/910000/ |k 1/910000/911600/ |p 3 | ||
| 998 | |g 1069693707 |a Rieger, Susanne |m 1069693707:Rieger, Susanne |d 910000 |d 910500 |e 910000PR1069693707 |e 910500PR1069693707 |k 0/910000/ |k 1/910000/910500/ |p 2 | ||
| 998 | |g 122639782 |a Billing, Heiko |m 122639782:Billing, Heiko |d 910000 |d 910500 |e 910000PB122639782 |e 910500PB122639782 |k 0/910000/ |k 1/910000/910500/ |p 1 |x j | ||
| 999 | |a KXP-PPN1578199182 |e 3020094852 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"17 August 2012","dateIssuedKey":"2012"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"extent":"9 S."}],"person":[{"family":"Billing","roleDisplay":"VerfasserIn","given":"Heiko","display":"Billing, Heiko","role":"aut"},{"given":"Susanne","role":"aut","display":"Rieger, Susanne","roleDisplay":"VerfasserIn","family":"Rieger"},{"role":"aut","display":"Süsal, Caner","given":"Caner","roleDisplay":"VerfasserIn","family":"Süsal"},{"roleDisplay":"VerfasserIn","family":"Waldherr","given":"Rüdiger","role":"aut","display":"Waldherr, Rüdiger"},{"given":"Gerhard","display":"Opelz, Gerhard","role":"aut","roleDisplay":"VerfasserIn","family":"Opelz"},{"family":"Wühl","roleDisplay":"VerfasserIn","role":"aut","display":"Wühl, Elke","given":"Elke"},{"display":"Tönshoff, Burkhard","role":"aut","given":"Burkhard","roleDisplay":"VerfasserIn","family":"Tönshoff"}],"name":{"displayForm":["Heiko Billing, Susanne Rieger, Caner Süsal, Rüdiger Waldherr, Gerhard Opelz, Elke Wühl and Burkhard Tönshoff"]},"relHost":[{"origin":[{"publisher":"Frontiers Media ; Springer ; Blackwell ; Wiley-Blackwell","dateIssuedDisp":"1988-","dateIssuedKey":"1988","publisherPlace":"Lausanne ; Berlin ; Heidelberg ; New York, NY ; Oxford [u.a.] ; Oxford [u.a.]"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"1165-1173","extent":"9","year":"2012","issue":"11","volume":"25","text":"25(2012), 11, Seite 1165-1173"},"disp":"IVIG and rituximab for treatment of chronic antibody-mediated rejection a prospective study in paediatric renal transplantation with a 2-year follow-upTransplant international","note":["Gesehen am 11.07.2022","Teils ungezählte Beil.: Supplement"],"id":{"eki":["254909744"],"doi":["10.1111/(ISSN)1432-2277"],"zdb":["1463183-0"],"issn":["1432-2277"]},"title":[{"title":"Transplant international","title_sort":"Transplant international","subtitle":"official journal of the European Society for Organ Transplantation and the European Liver Transplant Association"}],"recId":"254909744","pubHistory":["1.1988 -"]}],"recId":"1578199182","id":{"doi":["10.1111/j.1432-2277.2012.01544.x"],"eki":["1578199182"]},"title":[{"title":"IVIG and rituximab for treatment of chronic antibody-mediated rejection","title_sort":"IVIG and rituximab for treatment of chronic antibody-mediated rejection","subtitle":"a prospective study in paediatric renal transplantation with a 2-year follow-up"}],"note":["Published online: 17 August 2012","Gesehen am 02.08.2018"]} | ||
| SRT | |a BILLINGHEIIVIGANDRIT1720 | ||